Veloxis Pharmaceuticals Announces Initiation of ASERTAA Study of ENVARSUS ... GlobeNewswire (press release) Veloxis Pharmaceuticals A/S (OMX: VELO) today announced dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of ENVARSUS® (formerly LCP Tacro™) in kidney transplant recipients. |
